Stockpolly
Search
STLN · NASDAQ · Medical - Care Facilities

Starling Oncology (STLN)

Community cancer-care platform combining clinics, specialty pharmacy, and value-based payer contracts.

$5.95
Pre-market−0.14 (−2.30%)
At close$6.09(+2.53%)
Watchlist

  1. Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

    GlobeNewsWireProduct

    CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care's persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.

  2. Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

    Seeking Alpha

    Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript

  3. The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

    Zacks Investment Research

    The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.